Catastrophic antiphospholipid syndrome: treatment, prognosis, and the risk of relapse. Review uri icon

Overview

MeSH

  • Age Factors
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Bacterial Infections
  • Humans
  • Immunosuppression
  • Multiple Organ Failure
  • Plasmapheresis
  • Prognosis
  • Recurrence
  • Risk Factors
  • Rituximab
  • Treatment Outcome

MeSH Major

  • Adrenal Cortex Hormones
  • Antiphospholipid Syndrome
  • Immunoglobulins, Intravenous
  • Lupus Erythematosus, Systemic

abstract

  • The "catastrophic" variant of the antiphospholipid syndrome (APS) is characterized by multiple vascular occlusive events, usually affecting small vessels and developing over a short period of time. Although patients with catastrophic APS represent less than 1% of all patients with APS, they are usually in a life-threatening situation with a 50% mortality rate. The purpose of this paper is to review the treatment strategies and prognostic factors in patients with catastrophic APS. A detailed description of the clinical and laboratory features of the syndrome can be found in the other articles of this issue.

publication date

  • June 2009

has subject area

  • Adrenal Cortex Hormones
  • Age Factors
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Antiphospholipid Syndrome
  • Bacterial Infections
  • Humans
  • Immunoglobulins, Intravenous
  • Immunosuppression
  • Lupus Erythematosus, Systemic
  • Multiple Organ Failure
  • Plasmapheresis
  • Prognosis
  • Recurrence
  • Risk Factors
  • Rituximab
  • Treatment Outcome

Research

keywords

  • Journal Article
  • Review

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1007/s12016-008-8107-9

PubMed ID

  • 19051065

Additional Document Info

start page

  • 80

end page

  • 84

volume

  • 36

number

  • 2-3